Skip to content

Prevent CardioKids

Prevent CardioKids - Prevent CardioKids

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
NL-OMON
Registry ID
NL-OMON44875
Enrollment
420
Registered
2013-12-11
Start date
2014-02-05
Completion date
Unknown
Last updated
2024-04-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Co-morbidities overweight/ Vasculac function markers

Interventions

None listed

Sponsors

Medisch Universitair Ziekenhuis Maastricht
Lead Sponsor

Eligibility

Age
2 Years to 17 Years

Inclusion criteria

Inclusion criteria: - Participation in the COACH program - Aged between 6 and 18 years (at time of inclusion) - Overweight or obesity according to International Obesity Task Force (IOTF) criteria;For control group - Aged between 6 and 18 years - Normal weight according to the International Obesity Task Force (IOTF) criteria - Undergo surgery for elective reasons

Exclusion criteria

Exclusion criteria: Retardation Inflammatory disease: auto-immune diseases, inflammatory bowel diseases, hepatitis, dermatitis, nephritis, pancreatitis, gastro-enteritis, vasculitis, salpingitis, arthritis, osteomyelitis, myositis, ear-nose-throat infections Allergic disease: asthma, eczema, hay fever, food allergies Oncologic disease Cystic Fibrosis Type 1 Diabetes Mellitus Congenital metabolic disease Undernutrition

Design outcomes

Primary

MeasureTime frame
The primary endpoint is to examine the difference in micro- and macrovasculature characteristics in children with different weight classifications (lean; overweight; obese; extreme obese; morbid obese).

Secondary

MeasureTime frame
Secondary endpoints are differences in lipoprotein profiles, pro-inflammatory, fundus photography and OGTT profiles between different age groups, between lean and overweight/obese children and in relation with the measured micro- and macrovasculature characteristics

Countries

Netherlands

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP)